Compare REAL & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | VYGR |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 226.8M |
| IPO Year | 2019 | 2015 |
| Metric | REAL | VYGR |
|---|---|---|
| Price | $15.49 | $3.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $15.71 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 2.5M | 407.9K |
| Earning Date | 02-19-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $662,789,000.00 | $31,316,000.00 |
| Revenue This Year | $17.10 | N/A |
| Revenue Next Year | $10.90 | $71.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.30 | N/A |
| 52 Week Low | $4.61 | $2.65 |
| 52 Week High | $16.74 | $6.27 |
| Indicator | REAL | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 41.76 |
| Support Level | $15.81 | $3.93 |
| Resistance Level | $16.74 | $4.26 |
| Average True Range (ATR) | 0.78 | 0.20 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 55.15 | 15.13 |
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.